JSA advises Felix Pharma on Advent International’s $175 million investment

JSA Advocates & Solicitors advised Felix Pharmaceuticals in connection with a $175 million investment from Advent International for acquiring a significant minority stake in the company.

The transaction team was led by Sidharrth Shankar (Partner), with support from Prakriti Jaiswal (Partner), Anindita Basu (Principal Associate), Rishika Agarwal (Senior Associate), Eksha Narayan (Senior Associate), and Jatin Oberoi (Senior Associate).

Felix, founded in 2015, has built a portfolio of 14 US FDA-approved products and operates a USFDA-compliant manufacturing facility, with an injectables plant slated to go live by Q3 2025. The company has a global footprint with operations in Dublin, India, and the United States, and is aiming to tap into the underpenetrated generic veterinary drug segment.

Advent’s investment will support Felix’s R&D pipeline, expand manufacturing capacity, and enable broader global distribution. With less than 10% of pet medicines being generic, Advent sees significant growth potential in the space.

Advent International is a leading global private equity firm founded in 1984, with headquarters in Boston and over $90 billion in assets under management across 14 offices worldwide. The firm focuses on transformational buyouts, growth equity, and strategic restructurings in five core sectors—business & financial services, healthcare, industrial, consumer & leisure, and technology—often partnering with management teams to optimize operations and expand market presence.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.